These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
149 related articles for article (PubMed ID: 28760216)
1. Use of endpoint adjudication to improve the quality and validity of endpoint assessment for medical device development and post marketing evaluation: Rationale and best practices. A report from the cardiac safety research consortium. Seltzer JH; Heise T; Carson P; Canos D; Hiatt JC; Vranckx P; Christen T; Cutlip DE Am Heart J; 2017 Aug; 190():76-85. PubMed ID: 28760216 [TBL] [Abstract][Full Text] [Related]
2. Centralized adjudication of cardiovascular end points in cardiovascular and noncardiovascular pharmacologic trials: a report from the Cardiac Safety Research Consortium. Seltzer JH; Turner JR; Geiger MJ; Rosano G; Mahaffey KW; White WB; Sabol MB; Stockbridge N; Sager PT Am Heart J; 2015 Feb; 169(2):197-204. PubMed ID: 25641528 [TBL] [Abstract][Full Text] [Related]
3. Enabling social listening for cardiac safety monitoring: Proceedings from a drug information association-cardiac safety research consortium cosponsored think tank. Seifert HA; Malik RE; Bhattacharya M; Campbell KR; Okun S; Pierce C; Terkowitz J; Turner JR; Krucoff MW; Powell GE Am Heart J; 2017 Dec; 194():107-115. PubMed ID: 29223428 [TBL] [Abstract][Full Text] [Related]
4. Advancing medical device innovation through collaboration and coordination of structured data capture pilots: Report from the Medical Device Epidemiology Network (MDEpiNet) Specific, Measurable, Achievable, Results-Oriented, Time Bound (SMART) Think Tank. Reed TL; Drozda JP; Baskin KM; Tcheng J; Conway K; Wilson N; Marinac-Dabic D; Heise T; Krucoff MW Healthc (Amst); 2017 Dec; 5(4):158-164. PubMed ID: 27939170 [TBL] [Abstract][Full Text] [Related]
6. Unique device identifiers for coronary stent postmarket surveillance and research: a report from the Food and Drug Administration Medical Device Epidemiology Network Unique Device Identifier demonstration. Tcheng JE; Crowley J; Tomes M; Reed TL; Dudas JM; Thompson KP; Garratt KN; Drozda JP; Am Heart J; 2014 Oct; 168(4):405-413.e2. PubMed ID: 25262248 [TBL] [Abstract][Full Text] [Related]
7. Pediatric cardiovascular safety: challenges in drug and device development and clinical application. Bates KE; Vetter VL; Li JS; Cummins S; Aguel F; Almond C; Dubin AM; Elia J; Finkle J; Hausner EA; Joseph F; Karkowsky AM; Killeen M; Lemacks J; Mathis L; McMahon AW; Pinnow E; Rodriguez I; Stockbridge NL; Stockwell M; Tassinari M; Krucoff MW Am Heart J; 2012 Oct; 164(4):481-92. PubMed ID: 23067905 [TBL] [Abstract][Full Text] [Related]
8. Premarket clinical evaluation of novel cardiovascular devices: quality analysis of premarket clinical studies submitted to the Food and Drug Administration 2000-2007. Kramer DB; Mallis E; Zuckerman BD; Zimmerman BA; Maisel WH Am J Ther; 2010; 17(1):2-7. PubMed ID: 20038828 [TBL] [Abstract][Full Text] [Related]
9. Medical device reporting: the US final rule. Donawa ME Med Device Technol; 1996 Mar; 7(2):14-6, 18, 20-1. PubMed ID: 10159867 [TBL] [Abstract][Full Text] [Related]
10. FDA works to reduce preventable medical device injuries. Rados C FDA Consum; 2003; 37(4):29-33. PubMed ID: 12971346 [No Abstract] [Full Text] [Related]
11. Postmarketing surveillance of medical devices using Medicare claims. Malenka DJ; Kaplan AV; Sharp SM; Wennberg JE Health Aff (Millwood); 2005; 24(4):928-37. PubMed ID: 16012135 [TBL] [Abstract][Full Text] [Related]
12. Oversight overhaul: eliminating the premarket review of medical devices and implementing a provider-centered postmarket surveillance strategy. Scott B Food Drug Law J; 2011; 66(3):377-404, ii. PubMed ID: 24505854 [TBL] [Abstract][Full Text] [Related]
13. An evaluation of a distributed medical device safety surveillance system: the DELTA network study. Vidi VD; Matheny ME; Donnelly S; Resnic FS Contemp Clin Trials; 2011 May; 32(3):309-17. PubMed ID: 21356331 [TBL] [Abstract][Full Text] [Related]
14. Integration of new technology into clinical practice after FDA approval. Govil A; Hao SC J Interv Card Electrophysiol; 2016 Oct; 47(1):19-27. PubMed ID: 27565971 [TBL] [Abstract][Full Text] [Related]
15. FDA's revitalization of medical device review and regulation. Kessler DA Biomed Instrum Technol; 1994; 28(3):220-6. PubMed ID: 8061717 [No Abstract] [Full Text] [Related]
16. From the FDA: overview of Medical Device Data System rule. Biomed Instrum Technol; 2011; Suppl():15-8. PubMed ID: 21992038 [No Abstract] [Full Text] [Related]
17. Standardized endpoint definitions for Transcatheter Aortic Valve Implantation clinical trials: a consensus report from the Valve Academic Research Consortium. Leon MB; Piazza N; Nikolsky E; Blackstone EH; Cutlip DE; Kappetein AP; Krucoff MW; Mack M; Mehran R; Miller C; Morel MA; Petersen J; Popma JJ; Takkenberg JJ; Vahanian A; van Es GA; Vranckx P; Webb JG; Windecker S; Serruys PW J Am Coll Cardiol; 2011 Jan; 57(3):253-69. PubMed ID: 21216553 [TBL] [Abstract][Full Text] [Related]
18. Clinical event adjudication in cardiovascular device trials: An Food and Drug Administration perspective. Farb A; Zuckerman BD Am Heart J; 2017 Sep; 191():62-64. PubMed ID: 28888271 [No Abstract] [Full Text] [Related]
19. When do we need clinical endpoint adjudication in clinical trials? Held C Ups J Med Sci; 2019 Jan; 124(1):42-45. PubMed ID: 30427257 [TBL] [Abstract][Full Text] [Related]
20. Medical device regulatory landscape: the imperative of finding balance. Kaplan AV; Williams DO Circ Cardiovasc Interv; 2012 Feb; 5(1):2-5. PubMed ID: 22337999 [No Abstract] [Full Text] [Related] [Next] [New Search]